Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - carbidopa; levodopa - tablets - levodopa 250 mg; carbidopa 25 mg - levodopa - levodopa - for the relief of symptoms associated with parkinson's disease.

Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Европейски съюз - английски - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancerdocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

САЩ - английски - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 25 mg - venlafaxine tablets, usp is indicated for the treatment of major depressive disorder. the efficacy of venlafaxine tablets, usp in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iii-r category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see clinical trials ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the efficacy of 

САЩ - английски - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - clonazepam 0.125 mg - seizure disorders: clonazepam orally disintegrating tablet is useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam orally disintegrating tablets may be useful. in some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. in some cases, dosage adjustment may reestablish efficacy. panic disorder: clonazepam orally disintegrating tablet is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-v. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam orally disintegrating tablets was established in two 6-

САЩ - английски - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 10 mg - major depressive disorder paroxetine tablets, usp is indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets, usp in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology–clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets, usp in hospitalized depressed patients have not been adequ

Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 0.25 mcg - alfacalcidol - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.

Израел - английски - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 0.25 mcg - alfacalcidol - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.